Moderna has initiated the Phase 3 portion of its pivotal respiratory syncytial virus (RSV) vaccine trial: looking towards its ultimate goal to combine the vaccine with its COVID-19 and flu boosters into a single dose booster.
The Coalition for Epidemic Preparedness Innovations (CEPI) has launched a Call for Proposals to improve the thermostability of vaccines: with a particular interest in temperature-stable vaccine nasal sprays, microarray patches, or orally administered...
AES Clean Technology, a supplier of cleanroom facilities for the pharmaceutical and biopharmaceutical sectors, is ploughing $14.2m into a new US manufacturing facility.
US government agency, BARDA, is drawing on industry feedback to assist it in understanding the advanced developmental landscape of next-generation COVID-19 vaccines.
Contract development and manufacturing organization (CDMO), Recipharm, has acquired GenIbet, a Portuguese CDMO, specializing in the manufacture of biological clinical trial material.
Contract development and manufacturing organization (CDMO), Recipharm, says it has inked a deal with a top 10 big pharma company to support vaccine manufacturing from its facility in Kaysersberg, France.
Samsung Biologics flags further facility construction plans, with biologics, cell and gene therapies and next-generation vaccines to be the focus of those new sites.
Fujifilm Irvine Scientific, Inc, is to build a new bioprocessing center in China, with the goal of ensuring local cell culture media optimization support for vaccines, advanced therapies, and biotherapeutic drug development.
Medicago and GSK’s plant-based COVID-19 vaccine candidate has reported an overall efficacy rate of 71% in Phase 3 trials: with the final regulatory submission for the vaccine to be filed with Health Canada shortly.
A centralized testing approach, developed by the Coalition for Epidemic Preparedness Innovations (CEPI) and used by more than 30 COVID-19 vaccine developers, will be expanded to create a standardized evaluation model for other epidemic and pandemic disease...
The COVID-19 pandemic has reversed years of global progress in tackling tuberculosis and - for the first time in over a decade - TB deaths have increased. Research breakthroughs – such as new vaccines – are needed to rapidly reduce the number of new cases...
CEPI, the Coalition for Epidemic Preparedness Innovations, has announced the first funding awards under a $200m program to advance development of vaccines against SARS-CoV-2 variants and other betacoronaviruses.
Researchers at Stanford University and the University of North Carolina Chapel Hill are developing a microneedle vaccine patch that they believe could deliver a stronger immune response than a vaccine shot.
From industrializing mRNA manufacture to the implications of a potential IP waiver on COVID-19 vaccine production, hear from the experts in our free webinar this week.
The new alliance will focus on the development and manufacturing of complex medicines including biologics, vaccines, nucleic acids and cell and gene therapies; as well as looking to launch companies to advance the manufacture of such medicines.
The World Health Organization is recommending widespread use of the RTS,S/AS01 (RTS,S) vaccine among children in sub-Saharan Africa and other regions with moderate to high malaria transmission.
While several vaccines protect against meningitis, there remains an urgent need for innovation, funding and research to develop more meningitis-preventive vaccines, according to a new report from the WHO.
The biopharma industry continues to seek technologies that enable process control, while improving process development times and quality, says a Gamma Biosciences executive.
AstraZeneca has announced a long-term research collaboration with VaxEquity for the discovery, development and commercialization of its self-amplifying RNA (saRNA) therapeutics platform.
Catalent sees COVID-19 vaccines being an 'enduring and sustainable' revenue stream for the company, particularly with the advent of boosters, and the fact that developing countries, to date, have very low vaccination rates.
The International Vaccine Institute (IVI) and Bharat Biotech have started a Phase 2/3 clinical trial for a chikungunya vaccine candidate in Costa Rica.
Producers of CPhI North America 2021 offer a glimpse at programming, including sessions on COVID-19 challenges, supply chain issues, and more key topics.
Vaccine company Valneva has been awarded Breakthrough Therapy Designation for its single-shot chikungunya vaccine candidate, VLA1553, by the US Food and Drug Administration (FDA).
The G7 wants to see a 100-day response to future pandemics, including vaccines ready for deployment at scale in this time. ‘The three best weapons we have are diagnostics, therapeutics and vaccines’ says a report from the summit.
The World Health Organization (WHO) and the Swiss Confederation have launched the first WHO BioHub Facility to enhance the rapid sharing of viruses and other pathogens between laboratories and partners globally.
Gamma Biosciences has taken a controlling investment in Mirus Bio, an innovator and developer of biomimetic, cell-adaptive lipid-polymer nanocomplexes (LPNCs) for nucleic acid delivery based in Wisconsin in the US.
A Phase 2b trial for the University of Oxford’s malaria vaccine candidate showed 77% efficacy in children, according to a study published in The Lancet. ‘We believe this vaccine could have a major public health impact’, say researchers.
Sanofi will build a digitally-enabled, carbon-neutral vaccine manufacturing center in Singapore: designed to respond quickly to future pandemic risks and able to produce up to four vaccines simultaneously.
The 2020 Pfizer/BioNTech COVID-19 vaccine trial recruited more than 44,000 participants and reached submission for emergency authorization in 248 days: showing unprecedented speed and agility in the context of a global pandemic. So what have been the...
Collaboration is not an unknown in the domain of pharmaceutical development, but it is rare enough. The demands of the COVID-19 pandemic, however, have seen competitors switch to become manufacturing allies.
EU pharma industry representatives have expressed concern that the recently enacted EU export transparency mechanism could risk production delays or jeopardize the supply of COVID-19 vaccines in Europe.
A single-dose intranasal influenza vaccine is safe and produces a durable immune response, according to a Phase 1 study published in the Journal of Clinical Investigation this week.
The growing global pipeline of cell and gene therapy projects has prompted Thermo Fisher Scientific to invest again, with it announcing today that it had bought Henogen, Novasep’s viral vector manufacturing business based in Belgium, for about US$879.72m...
GlaxoSmithKline has started dosing patients in a Phase 3 clinical program investigating the safety and efficacy of its Respiratory Syncytial Virus (RSV) candidate vaccine for maternal immunisation.
Biotech funding kicked back into higher gear in October, pushing toward the summer monthly record highs with $10.5B raised, writes analyst firm, Jefferies
To support COVID-19 global preparedness, Stirling Ultracold is engaging directly with several pharmaceutical companies currently involved in COVID-19 vaccine development, with the idea of building a fleet of ULT freezers capable of storing their approved...
![WHO Director-General, Tedros Adhanom Ghebreyesus and Swiss Federal Councillor, Alain Berset, signed an agreement in relation to the BioHub on the edges of the World Health Assembly yesterday [May 24] © WHO/Christopher Black](/var/wrbm_gb_food_pharma/storage/images/_aliases/news_teaser_medium/publications/pharmaceutical-science/biopharma-reporter.com/article/2021/05/26/new-switzerland-hub-for-pathogen-storage-sharing-and-analysis/12512537-4-eng-GB/New-Switzerland-hub-for-pathogen-storage-sharing-and-analysis.jpg)
